Bayer Seeks Regulatory Approval for Aflibercept 8 mg in Two Major Retinal Eye Diseases in the EU

06

February

2023

|

10:59 AM

Europe/Amsterdam

Not intended for U.S. and UK Media

Exciting News!

Positive Results for Aflibercept 8 mg

We are thrilled to announce that we have filed for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on positive results of clinical trials, PULSAR and PHOTON.

 » …
Read More rnrn

Latest articles

Related articles